Please login to the form below

Not currently logged in
Email:
Password:

Keytruda

This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.

A look ahead to key trial readouts at ESMO

A look ahead to key trial readouts at ESMO

Keytruda continues to set the pace - but there are plenty of emerging and novel mechanisms. ... Merck &Co/MSD – already dominating non-small cell lung cancer with Keytruda (pembrolizumab) – will have overall survival data for its drug in first-line

Latest news

More from news
Approximately 110 fully matching, plus 162 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    AZ isn’t a frontrunner overall in lung cancer immunotherapy – MSD consolidated its global lead by gaining a groundbreaking approval of Keytruda in China in July – but AZ has an ace

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    their blockbuster checkpoint inhibitors Keytruda and Opdivo. ... CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which

  • Made in China Made in China

    In 2018 it has issued a flurry of approvals to new and innovative drugs such as MSD’s Keytruda and Pfizer’s Ibrance.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Last year, the FDA approved Merck’s Keytruda (pembrolizumab) as a first-line agent alongside chemotherapy for metastatic NSCLC on data showing the chance of cancer progression was cut in half. ... It’s also been shown to have improved efficacy when

  • 30 Women Leaders in UK Healthcare

    A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics